HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ICMAD Looks To Sway Legislators To Sessions Cosmetics Bill

This article was originally published in The Rose Sheet

Executive Summary

With letters to key legislators in the House and Senate, the Independent Cosmetic Manufacturers and Distributors looks to build support for the approach laid out in the Cosmetics Modernization Act of 2015, maintaining that the front-running Personal Care Products Safety Act is a danger to small business.

You may also be interested in...



ICMAD: Federal Cosmetics Legislation Without National Uniformity Not In Industry’s Interest

If the goal of bills like the proposed Personal Care Products Safety Act is to shore up consumers’ trust in the safety of cosmetic products, national uniformity is an indispensable component, says eos Products President Sanjiv Mehra, chairman of ICMAD’s board.

ICMAD Stands By House Cosmetics Bill, But May Be Ready To Negotiate

The Independent Cosmetic Manufacturers and Distributors calls Republican Senator Orrin Hatch's FDA Cosmetic Safety and Modernization Act "a step in the right direction," echoing the Personal Care Products Council's take on the proposal, signaling potential for industry solidarity at an auspicious moment in Washington.

Trump's Budget Blueprint: Cosmetics Opportunity Or Unhelpful Distraction?

President Trump appears to want greater user-fee contributions from FDA-regulated industries to offset cuts to federal spending in fiscal 2018. His recently released budget blueprint could complicate negotiations that cosmetics stakeholders were hoping to join, but it also could signal opportunity for an industry seeking increased regulation – and willing to pay for it.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel